In phytotherapy, the essential oil from the leaves of Alpinia zerumbet (Alpinia speciosa K. Schum.) (EOAZ) is used for neuropsychiatric symptoms, such as depression, stress and anxiety, and chronic problems that are associated with reproductive hormone imbalances in women. The chemical composition of EOAZ was analyzed by GC/MS, and the EOAZ properties inducing behavioral alterations in mice were examined by behavioral observations (BO) and an elevated plus-maze task (EPM), widely used as a method for assessing anxiolytic-like behaviors. Five major compounds, p-cymene (28.0 ± 5.0%), 1,8cineole (17.9 ± 4.2%), terpinen-4-ol (11.9 ± 6.3%), limonene (6.3 ± 2.2%), and camphor (5.2 ± 2.1%) were identified by retention indices, mass spectra and comparison with standards. Inhalational administration of EOAZ (8.7 ppm) induced unique jumping behaviors in mice. To further investigate the behavioral regulatory mechanisms of EOAZ, we administered an intraperitoneal injection of either 10 mg/kg 5-HTP or 10 mg/kg fluoxetine prior to the EOAZ inhalations. By 5-HTP or fluoxetine pretreatments, the jumping frequencies were significantly decreased. In EPM, EOAZ (0.087 and 8.7 ppm) obviously showed the anxiolytic-like activity in mice.
Alpinia zerumbet (Pers.) B.L. Burtt. et Sm., also called A. speciosa (J.C. Wendl.) K. Schum. , has been widely used in folk medicine in various subtropical regions, including Okinawa Island, Japan. It has been used in the treatment of intestinal and cardiovascular diseases such as hypertension [1a] . Previous studies on A. zerumbet have suggested that extracts of it have many biological activities, e.g., inhibition of the porphyrin photo-oxidative reaction [1b] and antifungal properties [1c] . The essential oil of A. zerumbet (EOAZ) is reported to have several biological activities including regulation of arterial pressure and antispasmodic action on smooth muscles [1d] . In phytotherapy, we use EOAZ mainly for neuropsychiatric symptoms, such as depression, stress and anxiety, which include chronic problems associated with reproductive hormone imbalances in women.
The chemical composition of EOAZ is presented in Table 1 . Seventeen compounds were characterized by retention indices, mass spectra and comparison with standards. The means and standard deviations were calculated with ten data from the EOAZ collected at different periods from December of 2002 to August 2007. The major constituents were characterized as p-cymene (28.0 ± 5.0%), 1,8-cineole (17.9 ± 4.2%), terpinen-4-ol (11.9 ± 6.3%), limonene (6.3 ± 2.2%), and camphor (5.2 ± 2.1%).
The behavioral alterations during each inhalational treatment with EOAZ (0.087 ppm, 0.87 ppm or 8.7 ppm) are shown in Figure 1 . During the 90-min EOAZ inhalation, behavioral changes were observed, which included increases in amount of immobilized time in the standing position and frequency of rearing. The inhalation of 0.087 ppm and 8.7 ppm EOAZ indicated the increasing tendency of a locomotor activity shown by the number of rearings in mice ( Figure 1 -A). In addition, frequent jumping behaviors originating after the 8.7 ppm EOAZ inhalation were especially noted (P < 0.05) ( Figure 1 -B). The jumps with knocking against the ceiling of the container were repeated. These frequent jumping behaviors, rarely observed as ordinary behavior in mice, increased depending upon the EOAZ concentrations. To investigate whether the jumping behaviors associated with the EOAZ inhalation were related to 5-hydroxytryptamine (5HT; serotonin) activity, we used two 5-HT related substances, 5hydroxytryptophan, (5-HTP), a precursor of 5-HT, and fluoxetine, a selective 5-HT reuptake inhibitor. Intraperitoneal injection of 10 mg/kg 5-HTP or 10 mg/kg fluoxetine prior to the 8.7 ppm EOAZ inhalation resulted in decreases of the EOAZassociated behavior observed. Both the 5-HTP (P < 0.05) and fluoxetine (P < 0.05) treatments drastically decreased the number of jumps during the inhalation of EOAZ without any pretreatments (Figure 1-B ). At this time, a significant decrease of jumping behaviors was admitted by pre-administering either 5-HTP or fluoxetine in a locomotor activity ( Figure 1-A) . Therefore, our results suggest that the jumping behaviors induced by EOAZ inhalation are related to the 5-HTergic system.
Several studies have reported jumping behaviors in mice. It has been reported that pituitary adenylate cyclase-activating polypeptide (PACAP), which is one of the neuro-polypeptides of the vasoactive intestinal peptide (VIP)/secretin/glucagon family [2a,2b] behavioral changes observed, such as frequent jumping behaviors and novelty seeking behaviors [2f] . It has also been reported that jumping behaviors are related to the dopaminergic system [2g]. In addition, MK801 (dizocilpine), an antagonist of the NMDA receptor, has been shown to elicit jumping behaviors in mice [2h,2i] . The possibility exists that there might be a correlation between the behavioral alterations, especially jumping behaviors, elicited by the activities of the neurotransmitters and neuroregulatory factors induced by the EOAZ inhalation.
In an elevated plus-maze task (EPM), widely used as a method for assessing anxiolytic-like behaviors, significant differences were not shown for any of the concentrations, even though the increasing tendency in the total invasion frequency to each arm was admitted in 0.087 ppm of EOAZ (Figure 2-A) . Figure  2-A,B) . It suggests that an anxiolytic-like effect of EOAZ is different from an effect with a conventional anxiolytic agent.
Furthermore, it has been reported that limonene [3b]
and linalool [3c], which are typical constituents of essential oils, have potency as anxiolytic agents.
Since limonene and linalool are constituents of EOAZ, they might play an important role in the anxiolytic-like effect of EOAZ. Because the appearance tendency is different depending on the concentration, the anxiolytic-like effect and the jumping behavior by EOAZ are suggested to be the action of different components. It is thought that part of the various actions of the essential oil that is multicomponent was clarified by this research.
Experimental
Plant materials: A. zerumbet plants were from the farms of Nihon Gettou Co., Ltd. in Okinawa, Japan. The aerial parts were collected at ten collection periods from December 2002 to August 2007.
Essential oil extraction and chemical composition:
The leaves of A. zerumbet were cut into small pieces about one square cm each, and used for the essential oil extraction. The essential oil was extracted by steam distillation for 1.5 h immediately after collection. EOAZ was obtained in yields of 0.03 -0.07% (v/w). EOAZ was also supplied by Green Flask Co., Ltd. (Tokyo, Japan). The various oils were analyzed by GC/MS (Clarus 500 GC/MS, PerkinElmer, Inc., MA, USA) under the following conditions: column: EQUITY-1 capillary column (30 m × 0.25 mm i.d., Supelco Inc, PA, USA); carrier gas: helium (1.24 mL/min); inlet line temperature: 250°C; source temperature: 230°C; column temperature: 60°C for 5 min, 60°C -240°C at 3°C/min, then 240°C for 5 min; mass spectra: electron impact, 70 eV. Individual components were identified by comparison with authentic standards and/or from the GC/MS NIST library [4a] .
Animals: ICR strain male 6-week-old mice (33.8 ± 1.8 g) were obtained from CLEA Japan, Inc. (Tokyo, Japan) and used after an adaptation period of 1 week. The mice were individually maintained under controlled conditions of temperature (24 ± 2°C) and light (12 h of light, 12 h of darkness; lights on from 08:00 -20:00 h) with free access to water and food. The mice had no prior experience with any of the essential oils and drugs. Each mouse was used once. From 5 to 8 mice were used for one experiment. Experimental protocols were conducted in accordance with the guidelines regarding the care of experimental animals, as approved by the Animal Research Committee at Toho University.
Inhalation of EOAZ:
A 55-mm-diameter filter paper (Whatman Japan K.K., Tokyo, Japan) was soaked with EOAZ and then set on the upper side of a glass container (L100×W225×H200 mm). After the adjustment period, mice were then exposed to EOAZ concentrations of 0.087 ppm, 0.87 ppm or 8.7 ppm. EOAZ inhalation was started 90 min prior to the EPM. The density of essential oil assumed that all the oils in the container evaporated at 24 ± 2°C and was calculated. The illuminance in the container was 200 Lx. Drug application: 5-HTP (10 mg/kg) (Sigma Aldrich Japan K.K., Tokyo, Japan), a precursor to the neurotransmitter 5-HT, was diluted with saline (0.9% w/v NaCl solution). Fluoxetine (10 mg/kg) (Sigma Aldrich Japan K.K.), a selective 5-HT reuptake inhibitor (SSRI), was also diluted with saline. Both drugs were injected intraperitoneally in a volume of 3.0 mL/kg at 30 min prior to the EOAZ inhalation [2e].
Behavioral observation (BO):
Each mouse was observed for 90 min during the EOAZ inhalation, and the frequencies of typical behaviors such as rearing, grooming, sleeping, defecating and urinating were counted. In BO, the rearing frequency of the mouse was converted into a locomotor activity. In addition, the unique jumping behavior was assessed.
Elevated plus-maze task (EPM):
The elevated plusmaze task consisted of two open arms (20 × 5 cm) and two closed arms (20 × 20 × 5 cm), with the open pair perpendicular to the closed one. The maze was made of wooden boards, while polyethylene terephthalate (PET) was used for the walls of the closed arms. The maze was located 60 cm above a floor. All tasks were carried out during the light period (13:00 -18:00), in a counterbalanced random order. Each mouse was placed at the center of the crossed arms, and then its behavior was recorded for 5 min with a web camera (BWC-30L01/SV USB, Buffalo Inc., Nagoya, Japan). The total of the invasion frequency to each arm was converted into a locomotor activity in EPM. The length of time each mouse spent in the open arms was measured. Increased time spent in the open arms was considered to reflect an anxiolytic-like effect [4b].
Statistical analysis: All results are expressed as the mean ± S.D. Statistical comparisons between the experimental groups were performed using the Mann-Whitney's U-test.
